Cargando…
Emerging Therapies for the Treatment of Psoriasis
Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over th...
Autores principales: | Patel, Mahir, Day, Antoinette, Warren, Richard B., Menter, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare Communications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/ https://www.ncbi.nlm.nih.gov/pubmed/23205338 http://dx.doi.org/10.1007/s13555-012-0016-4 |
Ejemplares similares
-
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015) -
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016) -
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022) -
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014) -
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)